Pharmaceutical composition having improved pharmacokinetic properties
Patent Information
- Application Number
- HK62026125106
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-21
- Filing Date
- 2026-06-22
- Publication Date
- 2026-09-11
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480059263.1 (22) Application Date 2024.09.20 (66) Domestic Priority Data 202311223970.3 2023.09.21 CN (85) PCT International Application Entering National Phase Date 2026.03.16 (86) PCT International Application Application Data PCT / CN2024 / 120008 2024.09.20 (87) PCT International Application Publication Data WO2025 / 061141 ZH 2025.03.27 (71) Applicant Sichuan Prite Pharmaceutical Co., Ltd. Address 610096 No. 566, Antai Fifth Road, High-tech Zone, Chengdu, Sichuan Province (72) Inventors: Liu Chengran, Wang Zhenyu, Wang Hairong, Yang Hao, Chen Yashu, Du Shuwen, Yang Anle, Zou Lianxin, Li Zerui (74) Patent Agency: Beijing Xinno Chuangcheng Intellectual Property Agency Co., Ltd. 11728 Patent Attorneys: Wang Yu, Chen Yuejun (51) Int.Cl. A61K 31 / 435 (2006.01) A61K 9 / 48 (2006.01) A61K 31 / 404 (2006.01) A61K 9 / 20 (2006.01) A61K 31 / 196 (2006.01) C07K 14 / 705 (2006.01) (54) Invention Title: Pharmaceutical Composition with Improved Pharmacokinetic Properties (57) Abstract: This disclosure provides a novel pharmaceutical composition, mainly composed of an alkyl glycoside and an active ingredient represented by Formula I. This invention unexpectedly discovered that the combined use of alkyl glycosides can significantly and unexpectedly improve multiple PK properties of the active ingredient shown in Formula I, such as a Cmax improvement of more than 10 times, even up to 52.2 times, an AUC0-inf improvement of more than 5.1 times, even up to 17.1 times, and a Tmax improvement that is shortened more rapidly to 0.17 h or less. Based on these excellent improved PK properties, bioavailability can be significantly enhanced and blood drug concentration can be rapidly increased, which is expected to further reduce the dosage and improve drug safety, especially for the treatment, relief and prevention of acute attacks of migraine and neuropathic pain. CN 121909031 A 2026.04.21 CN 1 21 90 90 31 A
